Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer

Keyphrases

• 5-fluorouracil (5-FU) 100%
• Phase II Trial 100%
• Mucositis 100%
• Biliary Tree 100%
• Gallbladder Cancer 100%
• Treatment Cycle 100%
• Interferon alpha-2b 100%
• Recombinant Interferon alpha-2b 100%
• Biliary Tract Cancer 100%
• Diarrhea 50%
• Chemotherapy 50%
• Adjuvant Therapy 50%
• Radiotherapy 50%
• Liver Transplantation 50%
• Disease Progression 50%
• Disease Status 50%
• Toxic Effects 50%
• Continuous Infusion 50%
• Complete Response 50%
• Subcutaneous Injection 50%
• Cholecystectomy 50%
• Median Time 50%
• Dermatitis 50%
• Partial Response 50%
• Median Survival Time 50%
• Venous Catheter 50%
• Decompression 50%
• Previously Untreated Patients 50%
• Prior Treatment 50%
• Fluorouracil 50%
• Granulocytopenia 50%
• Liver Resection 50%
• Asthenia 50%
• Drug Tolerance 50%
• Cholangiocarcinoma 50%

Medicine and Dentistry

• Phase II Trials 100%
• Interferon Alfa 2b 100%
• Biliary Tract Cancer 100%
• Gallbladder Carcinoma 66%
• Human Interferon 66%
• Mucositis 66%
• Malignant Neoplasm 33%
• Disease 33%
• Diarrhea 33%
• Radiation Therapy 33%
• Adjuvant Therapy 33%
• Disease Exacerbation 33%
• Subcutaneous Injection 33%
• Liver Transplantation 33%
• Continuous Infusion 33%
• Cholecystectomy 33%
• Hepatectomy 33%
• Toxicity 33%
• Dermatitis 33%
• Median Survival Time 33%
• Fluorouracil 33%
• Cholangiocarcinoma 33%
• Granulocytopenia 33%
• Asthenia 33%
• Drug Tolerance 33%
• Chemotherapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Phase II Trials 100%
• Alpha2b Interferon 100%
• Biliary Tract Cancer 100%
• Human Interferon 66%
• Mucosa Inflammation 66%
• Gallbladder Carcinoma 66%
• Malignant Neoplasm 33%
• Disease 33%
• Chemotherapy 33%
• Diarrhea 33%
• Disease Exacerbation 33%
• Toxicity 33%
• Subcutaneous Injection 33%
• Dermatitis 33%
• Median Survival Time 33%
• Fluorouracil 33%
• Bile Duct Carcinoma 33%
• Granulocytopenia 33%
• Drug Tolerability 33%
• Asthenia 33%